3 ASX Healthcare stocks to watch now

Ahead of the upcoming earnings releases, these ASX healthcare stocks are worth tracking as they may provide useful signals on growth trends and the overall outlook for the sector.

CSL Limited (ASX: CSL) 

showed early signs of stability as the share price rose 5.4% over the past one month after a brief correction.

For the year ended 30 June 2025, the company reported revenue of US$15.6 billion which represents 5% growth at constant currency while NPATA increased by 14% to US$3.3 billion.
Free cash flow rose by 58% to US$2.9 billion which was supported by stronger operating cash flow and lower capital expenditure.

Management announced several key initiatives which include a multi-year share buyback program, more than US$500 million in annual pre-tax savings by FY28 and plans to demerge CSL Seqirus by the end of FY26.

CSL guided to FY26 revenue growth of around 4 to 5% and NPATA growth of 7 to 10% at constant currency which is supported by strong immunoglobulin demand, continued expansion in CSL Vifor and improved conditions in the seasonal influenza business.

The current market capitalisation stands at US$87.93 billion and CSL Limited will announce its 2026 half year financial result on 11 February 2026 which should provide further clarity on execution progress.

Sigma Healthcare Limited (ASX: SIG) 

went through a transformational year after its merger with Chemist Warehouse Group in February 2025 which led to the creation of Australia’s largest retail pharmacy franchisor.
The merger combined Sigma’s wholesale and logistics strength with Chemist Warehouse’s retail execution which lifted scale and overall operating capability.

The stock has risen 7.48% over the past one month and the company also expanded its own and exclusive label product range with sales in this segment rising by more than 20% which supports margin expansion.

FY25 financial results reflected this step change in size as statutory revenue increased to $6 billion which represents growth of more than 80% year-on-year driven by the addition of Chemist Warehouse wholesale volumes and further retail network expansion.

The company has a market capitalisation of $36.48 billion and Sigma Healthcare will release its FY26 half year results for the period ending 31 December 2025 on 26 February 2026.

Fisher & Paykel Healthcare Corporation Limited (ASX: FPH) 

has a current market capitalisation of $19.89 billion and continues to stand out as a high-quality healthcare company supported by strong long-term growth drivers.

For the six months ended 30 September 2025, operating revenue increased 14% year-on-year to NZ$1.09 billion while net profit after tax rose 39% to NZ$213 million due to solid demand across both Hospital and Homecare segments.

Hospital revenue grew 17% to NZ$692.2 million on the back of strong consumables demand and changes in clinical practice while Homecare revenue increased 10% to NZ$395.9 million.
Margins improved during the period with gross margin rising to 63.0% and further upside could come from wider global use of high flow therapy, new Homecare product launches and progress on large scale infrastructure projects that support long term expansion.

Management reaffirmed full year guidance with operating revenue expected between NZ$2.17 billion and NZ$2.27 billion and net profit after tax between NZ$410 million and NZ$460 million.

(Source: Company Reports)